Cargando…

Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101

BACKGROUND: In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess neurocognitive functioning (NCF) in relation to...

Descripción completa

Detalles Bibliográficos
Autores principales: Caramanna, Ivan, de Kort, Julie M, Brandes, Alba A, Taal, Walter, Platten, Michael, Idbaih, Ahmed, Frenel, Jean Sebastien, Wick, Wolfgang, Preetha, Chandrakanth Jayachandran, Bendszus, Martin, Vollmuth, Philipp, Reijneveld, Jaap C, Klein, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290884/
https://www.ncbi.nlm.nih.gov/pubmed/35855458
http://dx.doi.org/10.1093/nop/npac022
_version_ 1784749013437775872
author Caramanna, Ivan
de Kort, Julie M
Brandes, Alba A
Taal, Walter
Platten, Michael
Idbaih, Ahmed
Frenel, Jean Sebastien
Wick, Wolfgang
Preetha, Chandrakanth Jayachandran
Bendszus, Martin
Vollmuth, Philipp
Reijneveld, Jaap C
Klein, Martin
author_facet Caramanna, Ivan
de Kort, Julie M
Brandes, Alba A
Taal, Walter
Platten, Michael
Idbaih, Ahmed
Frenel, Jean Sebastien
Wick, Wolfgang
Preetha, Chandrakanth Jayachandran
Bendszus, Martin
Vollmuth, Philipp
Reijneveld, Jaap C
Klein, Martin
author_sort Caramanna, Ivan
collection PubMed
description BACKGROUND: In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess neurocognitive functioning (NCF) in relation to corticosteroid treatment. METHODS: Using baseline data (ie, prior to randomization) of European Organization for Research and Treatment of Cancer (EORTC) trial 26101, we performed regression analysis to assess the predictive value of corticosteroid intake on performance of the EORTC brain tumor clinical trial NCF test battery. The battery is comprised of the Hopkins Verbal Learning Test—Revised (HVLT-R), Controlled Oral Word Association Test (COWA), and Trail Making Test (A and B). RESULTS: Out of 321 patients, 148 (46.1%) were not using corticosteroids, and 173 were using dexamethasone (34.3%), methylprednisolone (9.7%), or other corticosteroids (9.9%). Patients on corticosteroids had worse performance on all neurocognitive tests. Regression analyses demonstrated a negative association between corticosteroids use and the HVLT-R free recall score (R(2) change = 0.034, F change (1, 272) = 13.392, P < .001) and HVLT-R Delayed Recall score (R(2) change = 0.028, F change (1, 270) = 10.623, P = .002). No statistically significant association was found for HVLT-R Delayed recognition, COWA, TMT part A and TMT part B (P > .05). CONCLUSIONS: Glioblastoma patients prescribed with corticosteroids show poorer memory functions, expressive language, visual-motor scanning speed, and executive functioning than patients not using corticosteroids. Furthermore, we found a negative association between corticosteroid intake and memory functions. The possibility of deleterious effects of corticosteroids on NCF should be considered during clinical decision making.
format Online
Article
Text
id pubmed-9290884
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92908842022-07-18 Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 Caramanna, Ivan de Kort, Julie M Brandes, Alba A Taal, Walter Platten, Michael Idbaih, Ahmed Frenel, Jean Sebastien Wick, Wolfgang Preetha, Chandrakanth Jayachandran Bendszus, Martin Vollmuth, Philipp Reijneveld, Jaap C Klein, Martin Neurooncol Pract Original Articles BACKGROUND: In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess neurocognitive functioning (NCF) in relation to corticosteroid treatment. METHODS: Using baseline data (ie, prior to randomization) of European Organization for Research and Treatment of Cancer (EORTC) trial 26101, we performed regression analysis to assess the predictive value of corticosteroid intake on performance of the EORTC brain tumor clinical trial NCF test battery. The battery is comprised of the Hopkins Verbal Learning Test—Revised (HVLT-R), Controlled Oral Word Association Test (COWA), and Trail Making Test (A and B). RESULTS: Out of 321 patients, 148 (46.1%) were not using corticosteroids, and 173 were using dexamethasone (34.3%), methylprednisolone (9.7%), or other corticosteroids (9.9%). Patients on corticosteroids had worse performance on all neurocognitive tests. Regression analyses demonstrated a negative association between corticosteroids use and the HVLT-R free recall score (R(2) change = 0.034, F change (1, 272) = 13.392, P < .001) and HVLT-R Delayed Recall score (R(2) change = 0.028, F change (1, 270) = 10.623, P = .002). No statistically significant association was found for HVLT-R Delayed recognition, COWA, TMT part A and TMT part B (P > .05). CONCLUSIONS: Glioblastoma patients prescribed with corticosteroids show poorer memory functions, expressive language, visual-motor scanning speed, and executive functioning than patients not using corticosteroids. Furthermore, we found a negative association between corticosteroid intake and memory functions. The possibility of deleterious effects of corticosteroids on NCF should be considered during clinical decision making. Oxford University Press 2022-03-13 /pmc/articles/PMC9290884/ /pubmed/35855458 http://dx.doi.org/10.1093/nop/npac022 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Caramanna, Ivan
de Kort, Julie M
Brandes, Alba A
Taal, Walter
Platten, Michael
Idbaih, Ahmed
Frenel, Jean Sebastien
Wick, Wolfgang
Preetha, Chandrakanth Jayachandran
Bendszus, Martin
Vollmuth, Philipp
Reijneveld, Jaap C
Klein, Martin
Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
title Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
title_full Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
title_fullStr Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
title_full_unstemmed Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
title_short Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
title_sort corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: evidence from european organization for research and treatment of cancer (eortc) trial 26101
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290884/
https://www.ncbi.nlm.nih.gov/pubmed/35855458
http://dx.doi.org/10.1093/nop/npac022
work_keys_str_mv AT caramannaivan corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT dekortjuliem corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT brandesalbaa corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT taalwalter corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT plattenmichael corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT idbaihahmed corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT freneljeansebastien corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT wickwolfgang corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT preethachandrakanthjayachandran corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT bendszusmartin corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT vollmuthphilipp corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT reijneveldjaapc corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101
AT kleinmartin corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101